Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease
Public ClinicalTrials.gov record NCT05327803. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients With Treatment-refractory Mycobacterium Avium Complex Lung Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a pivotal Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR (Optimized Background Regimen) versus placebo + OBR in patients with treatment-refractory MAC lung disease. This study will enroll adult patients with treatment-refractory MAC lung disease who meet all eligibility criteria (including clinical, radiographic, and microbiological criteria).
Study identification
- NCT ID
- NCT05327803
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 177 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 20, 2022 (Actual)
- Primary completion
- Dec 18, 2024 (Actual)
- Completion
- Dec 18, 2024 (Actual)
- Last update posted
- Jun 10, 2026
2022 – 2024
United States locations
- U.S. sites
- 49
- U.S. states
- 29
- U.S. cities
- 42
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 423032 | Birmingham | Alabama | 35233 | — |
| 423037 | Tucson | Arizona | 85724 | — |
| 423070 | Sacramento | California | 95817 | — |
| 423069 | San Francisco | California | 94143 | — |
| 423006 | Stanford | California | 94305 | — |
| 423068 | Washington D.C. | District of Columbia | 20037 | — |
| 423075 | Bay Pines | Florida | 33744 | — |
| 423018 | DeLand | Florida | 32720 | — |
| 423034 | Kissimmee | Florida | 34746 | — |
| 423033 | Tampa | Florida | 33606 | — |
| 423054 | Tampa | Florida | 33612 | — |
| 423047 | Tampa | Florida | 33614 | — |
| 423038 | Vero Beach | Florida | 32960 | — |
| 423027 | Atlanta | Georgia | 30342 | — |
| 423076 | Indianapolis | Indiana | 46202 | — |
| 423029 | Iowa City | Iowa | 52242 | — |
| 423015 | Kansas City | Kansas | 66205 | — |
| 423063 | Wichita | Kansas | 67211 | — |
| 423065 | Jefferson | Louisiana | 70121 | — |
| 423042 | New Orleans | Louisiana | 70112 | — |
| 423060 | Baltimore | Maryland | 21201 | — |
| 423003 | Baltimore | Maryland | 21231 | — |
| 423074 | Boston | Massachusetts | 02114-2696 | — |
| 423061 | Boston | Massachusetts | 02115 | — |
| 423078 | Ann Arbor | Michigan | 48109 | — |
| 423031 | Rochester | Minnesota | 55902 | — |
| 423008 | St Louis | Missouri | 63110 | — |
| 423004 | Omaha | Nebraska | 68198 | — |
| 423009 | Lebanon | New Hampshire | 03756 | — |
| 423024 | Manhasset | New York | 11030 | — |
| 423014 | New York | New York | 10017 | — |
| 423013 | New York | New York | 10029 | — |
| 423071 | Chapel Hill | North Carolina | 27599 | — |
| 423072 | Charlotte | North Carolina | 28204 | — |
| 423017 | Durham | North Carolina | 27705 | — |
| 423039 | Winston-Salem | North Carolina | 27103 | — |
| 423079 | Cleveland | Ohio | 44195 | — |
| 423082 | Oklahoma City | Oklahoma | 73104 | — |
| 423007 | Portland | Oregon | 97239 | — |
| 423002 | Philadelphia | Pennsylvania | 19104 | — |
| 423058 | Philadelphia | Pennsylvania | 19107 | — |
| 423045 | Charleston | South Carolina | 29414 | — |
| 423001 | Charleston | South Carolina | 29425 | — |
| 423067 | Nashville | Tennessee | 37232 | — |
| 423081 | Fort Worth | Texas | 76104 | — |
| 423005 | Tyler | Texas | 75708 | — |
| 423012 | Charlottesville | Virginia | 22908 | — |
| 423080 | Edmonds | Washington | 98026 | — |
| 423011 | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05327803, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 10, 2026 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05327803 live on ClinicalTrials.gov.